2014-2015年度儿童接种减毒活流感疫苗与灭活流感疫苗的效果
在美国4个门诊点纳入2-17岁发热急性呼吸道疾病儿童,采用检测阴性设计比较四价减毒活流感疫苗(LAIV4)与灭活流感疫苗(IIV)的疫苗 effectiveness。对任何流感LAIV4调整VE为50%(95%CI 27-66%),IIV为39%(95%CI 18-54%);对A(H3N2)两者相似(LAIV4 30%,IIV 40%),对B型LAIV4为87%、IIV为29%。
要点
- 对任何流感LAIV4调整VE 50%(95%CI 27-66%),IIV为39%(95%CI 18-54%)。
- 对A(H3N2) LAIV4调整VE 30%(95%CI -6%至54%),IIV为40%(95%CI 16-58%)。
- 对B型LAIV4调整VE 87%(95%CI 63-96%),IIV为29%(95%CI -15%至56%)。
核心结论
- LAIV4与IIV对新的抗原变异A(H3N2)提供相似保护。
- LAIV4对漂移B型流感株的保护显著高于IIV。
研究设计与样本
- 2014-2015流感季节在美国4个门诊点纳入2-17岁、发热急性呼吸道疾病病程<5天的儿童。
- 鼻拭子采用逆转录聚合酶链反应检测流感,接种日期来自病历或免疫登记。
- 采用检测阴性设计估计VE,比较流感病例与检测阴性对照的接种比值比并调整潜在混杂因素。
- 共纳入1696名儿童,其中1511名(89%)纳入分析。
主要发现
- 427名(28%)儿童检出流感,其中317名为A(H3N2),110名为B型。
- 多数流感分离株为漂移的A(H3N2)株或漂移的B/Yamagata株。
- LAIV4对任何流感调整VE 50%(95%CI 27-66%),对A(H3N2) 30%(95%CI -6%至54%),对B型87%(95%CI 63-96%)。
- IIV对任何流感调整VE 39%(95%CI 18-54%),对A(H3N2) 40%(95%CI 16-58%),对B型29%(95%CI -15%至56%)。
- LAIV4相对于IIV的流感比值比:A(H3N2) OR 1.17(95%CI 0.73-1.86),B型OR 0.18(95%CI 0.06-0.55)。
关键数值与推荐
- LAIV4对任何流感调整VE 50%(95%CI 27-66%)。
- IIV对任何流感调整VE 39%(95%CI 18-54%)。
- LAIV4对A(H3N2)调整VE 30%(95%CI -6%至54%),IIV为40%(95%CI 16-58%)。
- LAIV4对B型调整VE 87%(95%CI 63-96%),IIV为29%(95%CI -15%至56%)。
- LAIV4 vs IIV对A(H3N2)的OR 1.17(95%CI 0.73-1.86),对B型的OR 0.18(95%CI 0.06-0.55)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A clinical study found that live attenuated influenza vaccine (LAIV) was superior to inactivated influenza vaccine (IIV) against drifted A(H3N2) viruses in children. During the 2014-2015 influenza season, widespread circulation of antigenically and genetically drifted A(H3N2) viruses provided an opportunity to evaluate subtype-specific vaccine effectiveness (VE) of quadrivalent LAIV (LAIV4) and IIV in children. METHODS: Children (2-17years) with febrile acute respiratory illness <5days' duration were enrolled at 4 outpatient sites in the United States during the 2014-2015 influenza season. Nasal swabs were tested for influenza by reverse transcription polymerase chain reaction; vaccination dates were obtained from medical records or immunization registries. VE was estimated using a test-negative design comparing odds of vaccination among influenza cases and test-negative controls with adjustment for potential confounders. RESULTS: Among 1696 children enrolled, 1511 (89%) were included in the analysis. Influenza was detected in 427 (28%) children; 317 had influenza A(H3N2) and 110 had influenza B. Most influenza isolates were characterized as a drifted strain of influenza A(H3N2) or a drifted strain of B/Yamagata. For LAIV4, adjusted VE was 50% (95% confidence interval [CI], 27-66%) against any influenza, 30% (95% CI, -6% to 54%) against influenza A(H3N2), and 87% (95% CI, 63-96%) against type B. For IIV, adjusted VE was 39% (95% CI, 18-54%) against any influenza, 40% (95% CI, 16-58%) against A(H3N2), and 29% (95% CI, -15% to 56%) against type B. Odds of influenza for LAIV4 versus IIV recipients were similar against influenza A(H3N2) (odds ratio [OR], 1.17; 95% CI, 0.73-1.86) and lower against influenza B (OR, 0.18; 95% CI, 0.06-0.55). CONCLUSIONS: LAIV4 and IIV provided similar protection against a new antigenic variant A(H3N2). LAIV4 provided significantly greater protection than IIV against a drifted influenza B strain. ClinicalTrials.gov identifier: NCT01997450.
引用
- McLean HQ, Caspard H, Griffin MR, et al. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children during the 2014-2015 season. Vaccine. 2017. PMID: 28408121. doi:10.1016/j.vaccine.2017.03.085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。